CureVac (NASDAQ:CVAC) Reaches New 1-Year Low at $3.35

CureVac (NASDAQ:CVACGet Free Report)’s share price reached a new 52-week low on Thursday . The stock traded as low as $3.35 and last traded at $3.37, with a volume of 599001 shares traded. The stock had previously closed at $3.42.

CureVac Stock Down 2.4 %

The company has a quick ratio of 3.41, a current ratio of 3.56 and a debt-to-equity ratio of 0.06. The company’s fifty day simple moving average is $3.80 and its 200 day simple moving average is $5.74.

Hedge Funds Weigh In On CureVac

A number of institutional investors and hedge funds have recently made changes to their positions in CVAC. China Universal Asset Management Co. Ltd. increased its stake in shares of CureVac by 95.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,738 shares of the company’s stock valued at $39,000 after purchasing an additional 2,804 shares in the last quarter. Vontobel Holding Ltd. bought a new stake in shares of CureVac during the fourth quarter valued at approximately $45,000. Optiver Holding B.V. increased its position in shares of CureVac by 2,407.0% during the third quarter. Optiver Holding B.V. now owns 6,844 shares of the company’s stock valued at $47,000 after acquiring an additional 6,571 shares in the last quarter. Pathstone Holdings LLC bought a new stake in shares of CureVac during the fourth quarter valued at approximately $55,000. Finally, Signaturefd LLC increased its position in shares of CureVac by 459.5% during the second quarter. Signaturefd LLC now owns 5,338 shares of the company’s stock valued at $56,000 after acquiring an additional 4,384 shares in the last quarter. Institutional investors own 15.76% of the company’s stock.

CureVac Company Profile

(Get Free Report)

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.

Featured Articles

Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.